View in EDS HTML Full Text PDF Full Text

Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization.

Saved in:
Bibliographic Details
Title: Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization.
Authors: Konrath KM; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America., Liaw K; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Tursi NJ; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America., McCanna ME; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Warner BM; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.; Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.; Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, Canada., Gary EN; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Zhu X; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Livingston C; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Monastra C; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Frase D; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Chokkalingam N; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Huynh A; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Shupin N; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Bayruns K; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Kriete S; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Kim A; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Park J; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Vendramelli R; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Truong T; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Tierney K; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Azaransky K; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Moffat E; National Center for Foreign Animal Disease (NCFAD), Canadian Food Inspection Agency, Winnipeg, Canada., Embury-Hyatt C; National Center for Foreign Animal Disease (NCFAD), Canadian Food Inspection Agency, Winnipeg, Canada., Beer LA; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Solanke O; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Walker SN; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Kalia R; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America., Tang HY; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America., Humeau LMPF; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America., Smith TRF; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America., Kobasa D; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada., Weiner DB; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America., Kulp DW; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Source: PLoS pathogens [PLoS Pathog] 2026 Feb 19; Vol. 22 (2), pp. e1013905. Date of Electronic Publication: 2026 Feb 19 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41712614
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Konrath+KM%22">Konrath KM</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Liaw+K%22">Liaw K</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Tursi+NJ%22">Tursi NJ</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22McCanna+ME%22">McCanna ME</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Warner+BM%22">Warner BM</searchLink>; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.; Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.; Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, Canada.<br /><searchLink fieldCode="AU" term="%22Gary+EN%22">Gary EN</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Zhu+X%22">Zhu X</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Livingston+C%22">Livingston C</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Monastra+C%22">Monastra C</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Frase+D%22">Frase D</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Chokkalingam+N%22">Chokkalingam N</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Huynh+A%22">Huynh A</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Shupin+N%22">Shupin N</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Bayruns+K%22">Bayruns K</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Kriete+S%22">Kriete S</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Kim+A%22">Kim A</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Park+J%22">Park J</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Vendramelli+R%22">Vendramelli R</searchLink>; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.<br /><searchLink fieldCode="AU" term="%22Truong+T%22">Truong T</searchLink>; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.<br /><searchLink fieldCode="AU" term="%22Tierney+K%22">Tierney K</searchLink>; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.<br /><searchLink fieldCode="AU" term="%22Azaransky+K%22">Azaransky K</searchLink>; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.<br /><searchLink fieldCode="AU" term="%22Moffat+E%22">Moffat E</searchLink>; National Center for Foreign Animal Disease (NCFAD), Canadian Food Inspection Agency, Winnipeg, Canada.<br /><searchLink fieldCode="AU" term="%22Embury-Hyatt+C%22">Embury-Hyatt C</searchLink>; National Center for Foreign Animal Disease (NCFAD), Canadian Food Inspection Agency, Winnipeg, Canada.<br /><searchLink fieldCode="AU" term="%22Beer+LA%22">Beer LA</searchLink>; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Solanke+O%22">Solanke O</searchLink>; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Walker+SN%22">Walker SN</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Kalia+R%22">Kalia R</searchLink>; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Tang+HY%22">Tang HY</searchLink>; Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Humeau+LMPF%22">Humeau LMPF</searchLink>; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Smith+TRF%22">Smith TRF</searchLink>; Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Kobasa+D%22">Kobasa D</searchLink>; Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.<br /><searchLink fieldCode="AU" term="%22Weiner+DB%22">Weiner DB</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.<br /><searchLink fieldCode="AU" term="%22Kulp+DW%22">Kulp DW</searchLink>; Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101238921%22">PLoS pathogens</searchLink> [PLoS Pathog] 2026 Feb 19; Vol. 22 (2), pp. e1013905. <i>Date of Electronic Publication: </i>2026 Feb 19 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101238921 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1553-7374 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215537366%22">15537366 </searchLink><i>NLM ISO Abbreviation: </i>PLoS Pathog <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41712614
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.ppat.1013905
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e1013905
    Titles:
      – TitleFull: Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Konrath KM
      – PersonEntity:
          Name:
            NameFull: Liaw K
      – PersonEntity:
          Name:
            NameFull: Tursi NJ
      – PersonEntity:
          Name:
            NameFull: McCanna ME
      – PersonEntity:
          Name:
            NameFull: Warner BM
      – PersonEntity:
          Name:
            NameFull: Gary EN
      – PersonEntity:
          Name:
            NameFull: Zhu X
      – PersonEntity:
          Name:
            NameFull: Livingston C
      – PersonEntity:
          Name:
            NameFull: Monastra C
      – PersonEntity:
          Name:
            NameFull: Frase D
      – PersonEntity:
          Name:
            NameFull: Chokkalingam N
      – PersonEntity:
          Name:
            NameFull: Huynh A
      – PersonEntity:
          Name:
            NameFull: Shupin N
      – PersonEntity:
          Name:
            NameFull: Bayruns K
      – PersonEntity:
          Name:
            NameFull: Kriete S
      – PersonEntity:
          Name:
            NameFull: Kim A
      – PersonEntity:
          Name:
            NameFull: Park J
      – PersonEntity:
          Name:
            NameFull: Vendramelli R
      – PersonEntity:
          Name:
            NameFull: Truong T
      – PersonEntity:
          Name:
            NameFull: Tierney K
      – PersonEntity:
          Name:
            NameFull: Azaransky K
      – PersonEntity:
          Name:
            NameFull: Moffat E
      – PersonEntity:
          Name:
            NameFull: Embury-Hyatt C
      – PersonEntity:
          Name:
            NameFull: Beer LA
      – PersonEntity:
          Name:
            NameFull: Solanke O
      – PersonEntity:
          Name:
            NameFull: Walker SN
      – PersonEntity:
          Name:
            NameFull: Kalia R
      – PersonEntity:
          Name:
            NameFull: Tang HY
      – PersonEntity:
          Name:
            NameFull: Humeau LMPF
      – PersonEntity:
          Name:
            NameFull: Smith TRF
      – PersonEntity:
          Name:
            NameFull: Kobasa D
      – PersonEntity:
          Name:
            NameFull: Weiner DB
      – PersonEntity:
          Name:
            NameFull: Kulp DW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 19
              M: 02
              Text: 2026 Feb 19
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1553-7374
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: PLoS pathogens
              Type: main
ResultId 1